Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
Sponsor: Yale University • ClinicalTrials.gov ID: NCT04131829
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The proposed randomized, double-blind research study will use functional magnetic resonance neuroimaging using state-of-the-art HCP acquisition protocols and analytic pipelines, to identify predictors and correlates of response to an accepted first-line pharmacological treatment for obsessive-compulsive disorder.
Interventions
-
Fluoxetine - immediate treatment
(Drug)
Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
-
Fluoxetine - delayed treatment
(Drug)
Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
Eligibility criteria
Conditions
Locations
- Yale OCD Research Clinic - CMHC/CNRU, 34 Park ST — New Haven, Connecticut, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record